Back to the portfolio

Pre-procedure 3D ablation zone prediction software

Biomedical DevicesComputing, Software & AIHealth & Safety TechPrototype likely

This technology is a software-based planning tool that predicts exactly where electrical energy will destroy tissue before a doctor actually performs the procedure. Before treatment, the system delivers a small test signal to measure how well the target tissue conducts electricity, then uses that real patient-specific data to calculate and display a 3D map of the tissue zone that will be affected. This replaces generic, one-size-fits-all estimates with a personalized prediction grounded in the actual electrical properties of each patient's tissue. The result is a visual treatment plan a physician can review and adjust before committing to the procedure.

What you could build

A pre-procedure planning software module integrated into ablation consoles or standalone clinical workstations that generates patient-specific 3D ablation zone previews; target buyers are medical device companies making IRE (irreversible electroporation), RF, or microwave ablation systems who need to differentiate on precision and safety.

Who in Virginia should care

Virginia-based health systems and interventional oncology centers (Inova, UVA Health) as clinical validation partners; defense-adjacent biomedical device contractors in the Northern Virginia corridor with medical electronics divisions.

Readiness: Prototype likely

Concept — described but not yet demonstrated. Lab validated — supported by experimental results in the patent. Prototype likely — the text describes a built, working embodiment.

Readiness is inferred from the patent text, not from a lab visit.

The record

Inventors
Paulo A. Garcia, Rafael V. Davalos
Granted
March 15, 2016
Status
Granted patent
Patent number
9283051

Ready to talk?

Virginia Tech Intellectual Properties handles licensing for this technology.

VTIP contact coming shortly

Prosim summaries are generated from public patent text and are not legal advice.